Pronunciation: ahn-DAN-SEH-trahn HIGH-droe-KLOR-ide
Class: 5-HT 3 receptor antagonist
- Tablets 16 mg
- Tablets 24 mg
- Injection 32 mg/50 mL
- Tablets 4 mg
- Tablets 8 mg
- Solution, oral 4 mg/5 mL (5 mg as hydrochloride dihydrate)
- Injection 2 mg/mL
- Tablets, orally-disintegrating 4 mg
- Tablets, orally-disintegrating 8 mg
- Film, oral 4 mg
- Film, oral 8 mg
Sandoz Ondansetron (Canada)
Selective serotonin (5-HT 3 ) receptor antagonist that inhibits serotonin receptors in GI tract or chemoreceptor trigger zone.
Passively and completely absorbed from GI tract. Bioavailability is 48% to 75% and is slightly enhanced with food.
C max for males is 24.1 to 37 ng/mL (8 mg oral dose). C max for females is 42.7 to 52.4 ng/mL (8 mg oral dose). C max for injection is 102 to 170 ng/mL. C max for the film is 37.28 ng/mL. T max for males is 2 to 4.1 h (8 mg dose). T max for females is 1.7 to 4.9 h (8 mg dose). T max for the film is 1.3 h.
Plasma protein binding is 70% to 76%.
Extensively metabolized in the liver by hydroxylation, followed by glucuronide or sulfate conjugation; CYP1A2, CYP2D6, CYP3A4 are the main hepatic enzymes.
Approximately 5% is eliminated as parent compound in urine. The half-life for males is 2.1 to 4.5 h (8 mg oral dose). The half-life for females is 1.9 to 6.2 h (8 mg dose). The half-life for injection is 3.5 to 5.5 h. Plasma Cl is 0.262 to 0.381 L/h/kg. The half-life for the film is 4.6 h.
Special PopulationsRenal Function Impairment
Mean plasma Cl is reduced by 50% in patients with severe renal impairment.Severe Renal Function Impairment
There is a reduction in Cl. Oral plasma Cl was reduced by 50%. No dosage adjustment is necessary.Hepatic Function Impairment
Cl is reduced 2- to 3-fold and the volume of distribution is increased. The half-life is increased to 20 h in patients with severe hepatic impairment. Bioavailability approaches 100%.Elderly
In elderly older than 75 y of age, there is a reduction in Cl and an increase in elimination half-life. No dosage adjustment is necessary.Gender
The extent and rate of absorption is greater in women than in men. There is slower Cl, a smaller volume of distribution, and higher bioavailability in women.
Indications and UsageParenteral and oral
Prevention of nausea and vomiting with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin; prevention of postoperative nausea or vomiting.Oral
Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen; prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin 50 mg/m 2 or more.
Treatment of nausea and vomiting associated with acetaminophen poisoning or prostacyclin therapy; treatment of acute levodopa-induced psychosis (visual hallucinations); reduction in bulimic episodes due to bulimia nervosa; treatment of spinal or epidural morphine-induced pruritus; management of social anxiety disorder.
Concomitant use with apomorphine ( Zuplenz only); hypersensitivity to ondansetron.
Dosage and AdministrationPrevention of Chemotherapy-Induced Nausea and Vomiting
IV 0.15 mg/kg infused over 15 min beginning 30 min before emetogenic chemotherapy with 2 additional 0.15 mg/kg doses 4 and 8 h after the first dose. Alternatively, infuse 32 mg over 15 min, starting 30 min prior to emetogenic chemotherapy.Adults and children 12 y of age and older
PO (moderately emetogenic cancer chemotherapy) 8 mg twice daily, administering the first dose 30 min prior to starting emetogenic chemotherapy and the second dose 8 h after the first dose; subsequent 8 mg doses may be given every 12 h for 1 to 2 days after completion of chemotherapy.Children 4 to 11 y of age
PO 4 mg 3 times daily, starting 30 min prior to chemotherapy, with subsequent doses 4 and 8 h after the first dose; give 4 mg every 8 h for 1 to 2 days after completion of chemotherapy.Prevention of Nausea and Vomiting due to Moderately Emetogenic Cancer Chemotherapy
PO 24 mg given 30 min prior to start of single-day highly emetogenic chemotherapy, including 50 mg/m 2 or more cisplatin.Prevention of Radiotherapy-Induced Nausea and Vomiting
PO 8 mg 3 times daily.Total Body Irradiation
PO 8 mg 1 to 2 h prior to each fraction of radiotherapy administered each day.Single High-Dose Fraction Radiotherapy to the Abdomen
PO 8 mg 1 to 2 h prior to radiotherapy, with subsequent doses every 8 h after the first dose for 1 to 2 days after completion of radiotherapy.Daily Fractionated Radiotherapy to the Abdomen
PO 8 mg 1 to 2 h prior to radiotherapy, with subsequent doses every 8 h after the first dose for each day radiotherapy is given.Prevention of Postoperative Nausea and Vomiting
IV 4 mg (undiluted) over 30 sec (preferably over 2 to 5 min) or IM 4 mg (undiluted) as a single injection. PO 16 mg as a single dose 1 h prior to induction of anesthesia.Children (2 to 12 y of age weighing 40 kg or less)
IV 0.1 mg/kgChildren (more than 40 kg)
IV 4 mg single dose. Administer over 30 sec or longer, preferably over 2 to 5 min.Hepatic Function Impairment
Severe Hepatic Impairment
PO Max, 8 mg/day.
IV Single 8 mg/day dose over 15 min beginning 30 min before chemotherapy.
- For oral use only. Do not chew or swallow.
- With dry hands, remove the film from the pouch and immediately place the film on top of the tongue where it dissolves in 4 to 20 sec.
- Once the film is dissolved, swallow with or without liquid.
- Wash hands after administration.
Store between 68° and 77°F.
Concomitant use is contraindicated.CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampicin)
Plasma levels of ondansetron may be reduced, decreasing the antiemetic effect.Tramadol
Concomitant use may result in reduced analgesic activity of tramadol.
Bradycardia (6%); hypotension (5%); chest pain, ECG changes, tachycardia, vascular occlusive events.
Headache (27%); drowsiness/sedation (20%); malaise/fatigue (13%); dizziness (7%); anxiety/agitation (6%); extrapyramidal symptoms, seizures, tonic-clonic seizures.
Pruritis (5%); rash (1%); flushing, urticaria (postmarketing).
Constipation (9%); diarrhea (7%); dry mouth, abdominal pain.
Gynecological disorder (7%); urinary retention (5%); oculogyric crisis (postmarketing).
AST and/or ALT elevated (2%), abnormal LFTs (postmarketing).
Anaphylaxis; hypersensitivity reactions, sometimes severe (eg, angioedema, shortness of breath, hypotension, laryngeal edema, stridor), laryngospasm, shock, cardiopulmonary arrest (postmarketing).
Hypoxia (9%), bronchospasm.
Wound problem (28%); fever (8%); shivers (5%); hiccups, transient blindness, weakness (postmarketing).
Category B .
Dosing in children younger than 4 y of age is not well defined.Zuplenz
Safety and efficacy for prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, radiotherapy, and/or prevention of postoperative nausea and/or vomiting not established for children; safety and efficacy of prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy not established in children younger than 4 y of age.
Anaphylaxis and bronchospasm have been reported.
Reduced doses required in severe hepatic impairment.
Transient ECG changes, including QT interval prolongation, have been reported rarely and predominately with IV use.
Ondansetron does not stimulate gastric or intestinal peristalsis; may mask progressive ileus or gastric distention.
Amaurosis, constipation, hypotension, vasovagal episode with transient second-degree heart block.
- Advise patient that headache is a common adverse reaction.
- Advise patient that medication will greatly reduce likelihood of nausea and vomiting, but that these are still possible.
- Advise patients that hypersensitivity reactions, some as severe as anaphylaxis and bronchospasm, have occurred.
Copyright © 2009 Wolters Kluwer Health.
More about ondansetron
- Ondansetron Hydrochloride (AHFS Monograph)
- Ondansetron (FDA)
- Ondansetron Injection (FDA)
- Ondansetron ODT (FDA)
- Ondansetron Oral Solution (FDA)
- Ondansetron and Dextrose (FDA)